hotspot -WSS

hotspot

author：Wikipedia 2025-09-06 02:10:22 - browse：116

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Hubble vs. James Webb telescope images: See the difference

WSS

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Health tech startups drop sharply from 2021 highs

STAT wants to know your pick for a great summer read or listen

Being 'nonadherent' patient made me a more empathetic doctor

Kaiser Permanente unions announce official strike date

Data show record exodus of life scientists from academia

explore

hotspot

Gilead needs Arcellx more than ever

focus

Jerome Adams on the need for new antivirals for Covid

Intercept Pharmaceuticals sells itself for less than $1 billion

Trump demands the U.S. pay no more for drugs than other countries … again

Biogen shutters digital health group, ends Apple study, in cost cutting move

At least 13 dead in Texas as scorching temps continue

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

BioMarin wins approval for gene therapy to treat hemophilia A

Covid vaccines: Private market messier than government rollout

How one medical school became remarkably diverse

Data show record exodus of life scientists from academia

knowledge

Shingles, which affected Dianne Feinstein, is on the rise

FDA advisers vote against ALS treatment from BrainStorm

Mindstrong's demise and the future of mental health care

Skip the lead apron during X

The biotech scorecard for Q3: 15 stock

Would Medicare drug price negotiations stall in a shutdown?

focus

knowledge

entertainment

hotspot